Preclinical Trial Testing Articles & Analysis
3 news found
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has ...
Abologix will use the CHF 150,000 to advance the preclinical development of its product, refine its commercial and competitive positioning, and strengthen its business development and fundraising efforts. ...
ByAbologix
Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat multidrug resistant organism infections and combat antibiotic resistance, today announced the selection of three Selux-crafted abstracts for poster sessions at the upcoming American Society for Microbiology, ASM Microbe 2019 scientific meeting on June 20-24 in San Francisco. "Selux Diagnostics is dedicated to ...